RxDoctor Payments Data

Harold Lipsky, MD

Gastroenterology · Rockville Centre, NYNPI 1528046133

Payments from drug & device makers

$9,669in general payments, 2019–2025

Across 612 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$825
  • Lilly USA, LLC$412
  • Ardelyx, Inc.$383
  • plus $3K from 29 others

What the payments were for

  • Speaking & faculty fees$200%
  • Grants$200%
  • Food & beverage$9,43298%
  • Education$1972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,669 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$179,507
Medicare patients
627
Services billed
1,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$316,492
LinzessLinaclotide236$174,382
XifaxanRifaximin35$79,221
RemicadeInfliximab12$67,409
CreonLipase/Protease/Amylase40$59,688
Famotidine783$29,021
MovantikNaloxegol Oxalate25$10,187
Mesalamine ErMesalamine44$9,987
Mesalamine35$9,051
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates126$7,745
Vancomycin Hcl11$7,161
Omeprazole360$6,488
Dexlansoprazole DrDexlansoprazole15$5,921
SutabSod Sulf/Pot Chloride/Mag Sulf33$5,280
Lubiprostone18$5,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$1,097$383,90126 claims
AbbVieLinzess, Creon$2,304$234,070276 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$825$79,22135 claims
Redhill Biopharma Inc.Movantik$189$10,18725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Rockville Centre

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →